Arkansas Judge Tim Fox found J&J and its subsidiary, Janssen, committed more than 238,000 violations of Arkansas’ Medicaid fraud laws while marketing Risperdal in a roughly four-year time span, beginning in 2002. The judge implemented a fine of $5,000 for each violation. The combined penalty is 11 percent of J&J’s 2011 net income.
A spokesperson for the Janssen unit of J&J said the company is “disappointed with the judge’s decision on the penalties.” The company plans to appeal if its motion for a new trial is denied.
More Articles on Pharmaceutical Companies:
Pfizer Nears Settlement Over Alleged Bribery
GlaxoSmithKline Settles Case Over Drug Pricing, Marketing With $3B
Pfizer Resolves False Claims Allegations With $14.5M Settlement
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
